After a respite, former leader Salix Pharmaceuticals rejoined Sector Leaders in Wednesday’s issue. Salix (SLXP) stock has been building the right side of an unusually steep base with the help of a few big up days in recent weeks. It’s still 19% off a Sept. 24 high, when it started shaping the 50% deep pattern. Salix rose 5% Tuesday on reports that Valeant Pharmaceuticals (VRX) is in talks to buy the gastroenterological drugmaker.